Skip to content

Nasdaq · CIK 0001829802

FTH Faeth Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing 28 d ago. Close $26.03 on Oct 9, 2026, +230% from the 52-week low and -35% from the high.

In brief

Faeth Therapeutics, Inc. (FTH) has 41 SEC Form 4 filings on file from 12 insiders, the latest filed on Sep 15, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

16 open-market trades have been scored at FTH. The newest: Brian C Stephenson (Chief Financial Officer) bought $326k of stock on Jun 29, 2026, filed Jul 1, 2026, scored 64 (notable). The largest of the 16 shown: Millennium Management LLC (10% owner) bought $818k on Mar 26, 2026, scored 39 (weak). 2 insiders bought within 14 days of each other around Jun 29, 2026.

8 Form 144 notices of planned sales are on file, the latest filed Aug 11, 2026.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company

Price and insider trades, last year

FTHOct 9, 2026 · close 26.03

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Faeth Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
64NotableBrian C Stephenson
Chief Financial Officer
buy
$326k
13,634 shares
+41%+241% from low-34% from high
69NotableBrian C Stephenson
Chief Financial Officer
buy
$401k
15,641 shares
+90%+261% from low-30% from high
62NotableBrian C Stephenson
Chief Financial Officer
buy
$406k
17,413 shares
-+241% from low-34% from high
43ModerateAnand Kiran Parikh
President and CEO
buy
$55k
2,806 shares
+0%+241% from low-34% from high
43ModerateCambrian BioPharma Inc
owner
sell
$501k
25,000 shares
-16%+230% from low-44% from high
43ModerateJames Peyer
owner, other
sell
$501k
25,000 shares
-16%+230% from low-44% from high
39WeakMillennium Management LLC
owner
buy
$818k
30,585 shares
+23%+365% from low-23% from high
21WeakMillennium Management LLC
owner
sell
$89k
3,250 shares
-2%+365% from low-23% from high
31WeakMillennium Management LLC
owner
buy
$382k
12,180 shares
+8%+445% from low-10% from high
20WeakMillennium Management LLC
owner
sell
$77k
2,741 shares
-2%+445% from low-10% from high
23WeakMillennium Management LLC
owner
buy
$141k
4,215 shares
+3%+437% from low-12% from high
36WeakMillennium Management LLC
owner
sell
$538k
17,076 shares
-12%+437% from low-12% from high
12WeakCambrian BioPharma Inc
owner
sell
$55k
6,612 shares
-4%-
12WeakJames Peyer
owner, other
sell
$55k
6,612 shares
-4%-
38WeakCambrian BioPharma Inc
owner
sell
$233k
21,295 shares
-12%-
38WeakJames Peyer
owner, other
sell
$233k
21,295 shares
-12%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Aug 11, 2026 Cambrian BioPharma Inc
10% Stockholder
130,142
9.71% of outstanding
$3.6MJul 22, 2026$501k
Apr 29, 2026 Cambrian BioPharma Inc
10% Stockholder
155,142
11.58% of outstanding
$5.0MApr 29, 2026none
Feb 24, 2026 Celebi John
Former Officer
3,374
0.27% of outstanding
$116kFeb 24, 2026$1.1M
Feb 18, 2026 Peyer James
Fomer Director
950
0.08% of outstanding
$26kFeb 18, 2026$6,707
Jan 27, 2026 RINGO WILLIAM R
Former Director
1,169
0.09% of outstanding
$11kJan 27, 2026none
Dec 9, 2025 Peyer James
Former Director
841
0.07% of outstanding
$6,707Dec 9, 2025$260k
Dec 4, 2025 Cambrian BioPharma Inc
10% Stockholder
21,222
1.68% of outstanding
$185kDec 4, 2025none
Dec 4, 2025 Cambrian BioPharma Inc
10% Stockholder
5,844
0.46% of outstanding
$51kDec 4, 2025none

Transactions

The newest 50 of 138 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 11, 2026Karen H Vousden
director
AGrant or award
Stock Option (right to buy)derivative
+25,000$0.00$025,00028 d ago
Jul 21, 2026Josiah Craver
PAO
AGrant or award
Performance-Based Stock Option (right to buy)derivative
+30,824$0.00$030,824Jul 23, 2026
Jul 21, 2026Anand Kiran Parikh
President and CEO
AGrant or award
Performance-Based Stock Option (right to buy)derivative
+398,018$0.00$0398,018Jul 23, 2026
Jun 29, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+831$23.34$19k33,885Jul 1, 2026
Jun 30, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,910$22.95$44k35,795Jul 1, 2026
Jun 30, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,638$23.88$39k37,433Jul 1, 2026
Jun 30, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+4,255$24.98$106k41,688Jul 1, 2026
Jul 1, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+4,400$23.40$103k46,088Jul 1, 2026
Jul 1, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+600$24.22$15k46,688Jul 1, 2026
Jun 24, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+2,891$25.22$73k20,304Jun 26, 2026
Jun 24, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+3,000$25.98$78k23,304Jun 26, 2026
Jun 24, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+3,400$26.98$92k26,704Jun 26, 2026
Jun 24, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+100$27.77$2,77726,804Jun 26, 2026
Jun 26, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+580$23.61$14k27,384Jun 26, 2026
Jun 26, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+4,212$24.90$105k31,596Jun 26, 2026
Jun 26, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,358$25.55$35k32,954Jun 26, 2026
Jun 26, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+100$26.39$2,63933,054Jun 26, 2026
Jun 22, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,797$20.23$36k1,797Jun 24, 2026
Jun 22, 2026Anand Kiran Parikh
President and CEO
POpen-market purchase
Common Stock
+2,806$19.76$55k764,234Jun 24, 2026
Jun 22, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,118$20.82$23k2,915Jun 24, 2026
Jun 22, 2026Anand Kiran Parikh
President and CEO
MOption exercise
Common Stock
+45,252$1.16$52k809,486Jun 24, 2026
Jun 22, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,583$22.40$35k4,498Jun 24, 2026
Jun 22, 2026Anand Kiran Parikh
President and CEO
MOption exercise
Common Stock
+8,213$1.16$9,527817,699Jun 24, 2026
Jun 22, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+3,329$23.28$77k7,827Jun 24, 2026
Jun 22, 2026Anand Kiran Parikh
President and CEO
MOption exercise
Employee Stock Option (right to buy)derivative
-45,252$0.00$091,632Jun 24, 2026
Jun 22, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+356$23.95$8,5268,183Jun 24, 2026
Jun 22, 2026Anand Kiran Parikh
President and CEO
MOption exercise
Employee Stock Option (right to buy)derivative
-8,213$0.00$04,107Jun 24, 2026
Jun 23, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+6,836$24.12$165k15,019Jun 24, 2026
Jun 23, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+1,969$24.84$49k16,988Jun 24, 2026
Jun 23, 2026Brian C Stephenson
Chief Financial Officer
POpen-market purchase
Common Stockindirect: See footnote
+425$25.91$11k17,413Jun 24, 2026
Jun 15, 2026Anand Kiran Parikh
President and CEO
CConversion
Common Stock
+761,428--761,428Jun 16, 2026
Jun 12, 2026Saira Ramasastry
director
AGrant or award
Stock Option (right to buy)derivative
+25,000$0.00$025,000Jun 16, 2026
Feb 17, 2026Anand Kiran Parikh
President and CEO
AGrant or award
Series B Preferred Stockderivative
+761--761,428Jun 16, 2026
Jun 15, 2026Stephen M. Hahn
director
CConversion
Common Stock
+44,763--44,763Jun 16, 2026
Jun 15, 2026Anand Kiran Parikh
President and CEO
CConversion
Series B Preferred Stockderivative
-761--0Jun 16, 2026
Jun 12, 2026Stephen M. Hahn
director
AGrant or award
Stock Option (right to buy)derivative
+25,000$0.00$025,000Jun 16, 2026
Feb 17, 2026Anand Kiran Parikh
President and CEO
AGrant or award
Employee Stock Option (right to buy)derivative
+12,320--12,320Jun 16, 2026
Jun 15, 2026Stephen M. Hahn
director
CConversion
Series B Preferred Stockderivative
-45--0Jun 16, 2026
Feb 17, 2026Anand Kiran Parikh
President and CEO
AGrant or award
Employee Stock Option (right to buy)derivative
+136,884--136,884Jun 16, 2026
Jun 10, 2026Phillip B. Donenberg
director
AGrant or award
Stock Option (right to buy)derivative
+12,500$0.00$012,500Jun 12, 2026
Jun 10, 2026Christopher Gerry
President & PEO
AGrant or award
Stock Option (right to buy)derivative
+220,000$0.00$0220,000Jun 12, 2026
Jun 10, 2026Bob Holmen
director
AGrant or award
Stock Option (right to buy)derivative
+12,500$0.00$012,500Jun 12, 2026
Jun 1, 2026Cambrian BioPharma Inc
owner
SOpen-market sale
Common Stock
-24,524$20.00$490k130,618Jun 1, 2026
Jun 1, 2026James Peyer
owner, other
SOpen-market sale
Common Stock
-24,524$20.00$490k130,618Jun 1, 2026
Jun 1, 2026Cambrian BioPharma Inc
owner
SOpen-market sale
Common Stock
-476$21.14$10k130,142Jun 1, 2026
Jun 1, 2026James Peyer
owner, other
SOpen-market sale
Common Stock
-476$21.14$10k130,142Jun 1, 2026
Apr 2, 2026Millennium Management LLC
owner
POpen-market purchase
Common Stockindirect: See Footnote
+26$33.47$870144,974May 15, 2026
Mar 26, 2026Millennium Management LLC
owner
POpen-market purchase
Common Stockindirect: See footnote
+778$27.23$21k131,370May 15, 2026
Mar 31, 2026Millennium Management LLC
owner
POpen-market purchase
Common Stockindirect: See footnote
+616$24.69$15k146,657May 15, 2026
Mar 26, 2026Millennium Management LLC
owner
POpen-market purchase
Common Stockindirect: See footnote
+1,327$27.95$37k131,370May 15, 2026
50 of 138 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about FTH

Answered from the filings on this page, as of the latest one.

Are insiders buying FTH?

No. In the last 90 days no insider at Faeth Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade FTH on the open market?

Brian C Stephenson (Chief Financial Officer) bought $326k of FTH on Jun 29, 2026 and filed the Form 4 on Jul 1, 2026. InsiderTell scored 64 (notable), with 2 insiders on the same side within 14 days.

How many insiders file Form 4 at Faeth Therapeutics, Inc.?

12 people have filed a Form 4 at Faeth Therapeutics, Inc., among them Cambrian BioPharma Inc (10% owner), Josiah Craver (PAO), Phillip B. Donenberg (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

FTH insider trading: Faeth Therapeutics, Inc. | InsiderTell